Xeris Pharmaceuticals, Inc. (XERS): Price and Financial Metrics
XERS Stock Summary
- Xeris Pharmaceuticals Inc's stock had its IPO on June 21, 2018, making it an older stock than merely 6.62% of US equities in our set.
- As for revenue growth, note that XERS's revenue has grown 792.08% over the past 12 months; that beats the revenue growth of 99.02% of US companies in our set.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for XERS comes in at -58.32% -- higher than that of only 6.29% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Xeris Pharmaceuticals Inc, a group of peers worth examining would be AVGR, EYPT, RWLK, HTGM, and MBII.
- Visit XERS's SEC page to see the company's official filings. To visit the company's web site, go to www.xerispharma.com.
XERS Stock Price Chart Interactive Chart >
XERS Price/Volume Stats
|Current price||$4.18||52-week high||$9.69|
|Prev. close||$4.21||52-week low||$1.42|
|Day high||$4.27||Avg. volume||1,855,629|
|50-day MA||$5.20||Dividend yield||N/A|
|200-day MA||$3.89||Market Cap||204.72M|
Xeris Pharmaceuticals, Inc. (XERS) Company Bio
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company’s lead product candidate is glucagon rescue pen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise self-administered glucagon that is in Phase IIa clinical trials for the treatment of post-bariatric hypoglycemia; continuous glucagon, which is in Phase II clinical trials for the treatment of congenital hyperinsulinism; continuous glucagon that is in Phase IIa clinical trials for the treatment of hypoglycemia-associated autonomic failure; self-administered glucagon, which is in Phase IIa clinical trials for the treatment of exercise-induced hypoglycemia; and ready-to-use glucagon that is in Phase II clinical trials for use in a bi-hormonal artificial pancreas closed-loop systems. The company’s preclinical programs include ready-to-use diazepam, a ready-to-use diazepam formulation for the treatment of ARS in patients with epilepsy; and pram-insulin, a ready-to-use fixed dose combination of insulin and pramlintide. It serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.